Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

The Spot Sign for Predicting and Treating ICH Growth Study

NCT00810888 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to determine if computed tomography angiography can predict which individuals with intracerebral hemorrhage will experience significant growth in the size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study will compare the drug recombinant activated factor VII (rFVIIa) to placebo to determine the effect of rFVIIa on intracerebral hemorrhage growth.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG recombinant activated factor VII

Study Locations (10)

Pennsylvania

  • University of Pennsylvania — Philadelphia
  • University of Pittsburgh Medical Center — Pittsburgh

Arizona

  • St. Joseph's Hospital and Medical Center — Phoenix

California

  • University of California, San Diego — San Diego

Massachusetts

  • Massachusetts General Hospital — Boston

Missouri

  • Washington University — St Louis

Ohio

  • University of Cincinnati-Clinical Coordinating Center — Cincinnati

South Carolina

  • Medical University of South Carolina — Charleston

Alberta

  • University of Calgary — Calgary

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2010-11
Est. Completion 2016-04
Phase Phase 2

Sponsor

University of Cincinnati

179 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00810888

The ClinicalTrials.gov registry entry for NCT00810888 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 179 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Intracerebral Hemorrhage appearing as the primary indexed condition, and to 2 interventions — of which placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00810888 reports 10 study locations spanning 9 distinct geographic areas — top geographies include Pennsylvania, Arizona, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00810888 about?

NCT00810888 is a clinical study titled "The Spot Sign for Predicting and Treating ICH Growth Study". The purpose of this study is to determine if computed tomography angiography can predict which individuals with intracerebral hemorrhage will experience significant growth in the size of the hemorrhage. For individuals who are at high risk for hemorrhage growth, the study will compare the drug recom...

What is the current status of trial NCT00810888?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2010-11. Estimated completion is 2016-04.

What conditions does trial NCT00810888 study?

This clinical trial studies the following conditions: Intracerebral Hemorrhage. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00810888?

The interventions under investigation include: placebo (DRUG), recombinant activated factor VII (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00810888?

This trial is sponsored by University of Cincinnati, which has 179 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00810888 being conducted?

This trial has 10 study locations across Arizona, California, Massachusetts, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial